Literature DB >> 26124979

HIV-associated neurocognitive disorders: Five new things.

Jeffrey A Rumbaugh1, William Tyor1.   

Abstract

HIV-associated neurocognitive disorders (HAND) remain an important cause of cognitive dysfunction. Current nomenclature for HAND includes HIV-associated dementia and milder forms known as asymptomatic neurocognitive impairment (ANI) and mild neurocognitive disorder (MND). ANI and MND remain highly prevalent despite combined antiretroviral therapy (cART). These mild forms of HAND must be diagnosed through neuropsychological testing. If a patient has HAND, it remains unclear whether using a cART regimen with theoretically superior CNS penetration improves the prognosis. Nevertheless, a CNS penetration effectiveness score for antiretrovirals is available. Other factors to consider when diagnosing and treating HIV infection and HAND include the HIV clade or subtype. Data suggest that HAND occurs more often in association with certain clades, and higher vigilance for cognitive dysfunction may be recommended. Finally, comorbidities, such as diseases associated with advanced age, other infections, and drug abuse, need to be considered as cofactors for cognitive dysfunction and treated accordingly.

Entities:  

Year:  2015        PMID: 26124979      PMCID: PMC4469345          DOI: 10.1212/CPJ.0000000000000117

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN: 2163-0402


  20 in total

Review 1.  Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force.

Authors: 
Journal:  Neurology       Date:  1991-06       Impact factor: 9.910

Review 2.  Effect of HIV clade differences on the onset and severity of HIV-associated neurocognitive disorders.

Authors:  William Tyor; Cari Fritz-French; Avindra Nath
Journal:  J Neurovirol       Date:  2013-10-16       Impact factor: 2.643

Review 3.  Do alcohol and cocaine abuse alter the course of HIV-associated dementia complex?

Authors:  W R Tyor; L D Middaugh
Journal:  J Leukoc Biol       Date:  1999-04       Impact factor: 4.962

4.  Hepatitis C virus co-infection increases neurocognitive impairment severity and risk of death in treated HIV/AIDS.

Authors:  Pornpun Vivithanaporn; Krista Nelles; Leah DeBlock; Stephen C Newman; M John Gill; Christopher Power
Journal:  J Neurol Sci       Date:  2011-09-17       Impact factor: 3.181

5.  Antiretroviral therapy improves cognitive impairment in HIV+ individuals in sub-Saharan Africa.

Authors:  N Sacktor; N Nakasujja; R Skolasky; K Robertson; M Wong; S Musisi; A Ronald; E Katabira
Journal:  Neurology       Date:  2006-07-25       Impact factor: 9.910

6.  Clinical-neuropathologic correlation in HIV-associated dementia.

Authors:  J D Glass; S L Wesselingh; O A Selnes; J C McArthur
Journal:  Neurology       Date:  1993-11       Impact factor: 9.910

7.  Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA.

Authors:  Ronald J Ellis; David J Moore; Meredith E Childers; Scott Letendre; J Allen McCutchan; Tanya Wolfson; Stephen A Spector; Karen Hsia; Robert K Heaton; Igor Grant
Journal:  Arch Neurol       Date:  2002-06

8.  Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.

Authors:  Scott Letendre; Jennifer Marquie-Beck; Edmund Capparelli; Brookie Best; David Clifford; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Igor Grant; Ronald J Ellis
Journal:  Arch Neurol       Date:  2008-01

Review 9.  Evolution of HIV dementia with HIV infection.

Authors:  Avindra Nath; Nicoline Schiess; Arun Venkatesan; Jeffrey Rumbaugh; Ned Sacktor; Justin McArthur
Journal:  Int Rev Psychiatry       Date:  2008-02

10.  Clade C HIV-1 isolates circulating in Southern Africa exhibit a greater frequency of dicysteine motif-containing Tat variants than those in Southeast Asia and cause increased neurovirulence.

Authors:  Vasudev R Rao; Ujjwal Neogi; Joshua S Talboom; Ligia Padilla; Mustafizur Rahman; Cari Fritz-French; Sandra Gonzalez-Ramirez; Anjali Verma; Charles Wood; Ruth M Ruprecht; Udaykumar Ranga; Tasnim Azim; John Joska; Eliseo Eugenin; Anita Shet; Heather Bimonte-Nelson; William R Tyor; Vinayaka R Prasad
Journal:  Retrovirology       Date:  2013-06-08       Impact factor: 4.602

View more
  22 in total

1.  Antiretroviral therapy adherence and self-efficacy among people living with HIV and a history of drug use in Vietnam.

Authors:  Li Li; Chunqing Lin; Sung-Jae Lee; Le Anh Tuan; Nan Feng; Nguyen Anh Tuan
Journal:  Int J STD AIDS       Date:  2017-03-03       Impact factor: 1.359

2.  Neurocognitive Impairment in the Combined Antiretroviral Therapy Era in a Romanian Cohort of Young Adults with Chronic HIV Infection.

Authors:  Aura Temereanca; Luminita Ene; Adelina Rosca; Carmen C Diaconu; Anca Luca; Ruxandra Burlacu; Roxana Radoi; Adina Bulacu-Talnariu; Thomas D Marcotte; Cristian L Achim; Simona Ruta
Journal:  AIDS Res Hum Retroviruses       Date:  2019-10-08       Impact factor: 2.205

3.  Global HIV neurology: a comprehensive review.

Authors:  Kiran T Thakur; Alexandra Boubour; Deanna Saylor; Mitashee Das; David R Bearden; Gretchen L Birbeck
Journal:  AIDS       Date:  2019-02-01       Impact factor: 4.177

4.  Δ9-Tetrahydrocannabinol Suppresses Secretion of IFNα by Plasmacytoid Dendritic Cells From Healthy and HIV-Infected Individuals.

Authors:  Joseph E Henriquez; Michael D Rizzo; Matthias A Schulz; Robert B Crawford; Peter Gulick; Norbert E Kaminski
Journal:  J Acquir Immune Defic Syndr       Date:  2017-08-15       Impact factor: 3.731

Review 5.  Targeting Cannabinoid Receptor 2 on Peripheral Leukocytes to Attenuate Inflammatory Mechanisms Implicated in HIV-Associated Neurocognitive Disorder.

Authors:  Michael D Rizzo; Joseph E Henriquez; Lance K Blevins; Anthony Bach; Robert B Crawford; Norbert E Kaminski
Journal:  J Neuroimmune Pharmacol       Date:  2020-05-14       Impact factor: 4.147

6.  The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model.

Authors:  Woldeab B Haile; Christina Gavegnano; Sijia Tao; Yong Jiang; Raymond F Schinazi; William R Tyor
Journal:  Neurobiol Dis       Date:  2016-02-03       Impact factor: 5.996

Review 7.  The Impact of Antiretroviral Therapy on Neurocognitive Outcomes Among People Living with HIV in Low- and Middle-Income Countries (LMICs): A Systematic Review.

Authors:  Henry Ukachukwu Michael; Sasha Naidoo; Kofi Boamah Mensah; Suvira Ramlall; Frasia Oosthuizen
Journal:  AIDS Behav       Date:  2021-02

8.  Cognitive and motor deficits in older adults with HIV infection: Comparison with normal ageing and Parkinson's disease.

Authors:  Eva M Müller-Oehring; Rosemary Fama; Taylor F Levine; Cheshire Hardcastle; Ryan Goodcase; Talora Martin; Varsha Prabhakar; Helen M Brontë-Stewart; Kathleen L Poston; Edith V Sullivan; Tilman Schulte
Journal:  J Neuropsychol       Date:  2020-10-08       Impact factor: 2.864

Review 9.  A mouse model of HIV-associated neurocognitive disorders: a brain-behavior approach to discover disease mechanisms and novel treatments.

Authors:  William R Tyor; Heather Bimonte-Nelson
Journal:  J Neurovirol       Date:  2017-09-11       Impact factor: 2.643

10.  HIV-infected cannabis users have lower circulating CD16+ monocytes and IFN-γ-inducible protein 10 levels compared with nonusing HIV patients.

Authors:  Michael D Rizzo; Robert B Crawford; Joseph E Henriquez; Yasser A Aldhamen; Peter Gulick; Andrea Amalfitano; Norbert E Kaminski
Journal:  AIDS       Date:  2018-02-20       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.